Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad to go ahead with business split

This article was originally published in Clinica

Executive Summary

Myriad Genetics has received the green light from its board of directors to proceed with the planned spin-off of its research and drug development units. The move is expected to maximise the potential of Myriad's core's molecular diagnostics business, which has seen its revenues growing steadily over the last several quarters. This business will operate as Myriad Genetics, and trade under the new ticker symbol MGX. It will have 800 employees and five marketed diagnostics products – BRACAnalysis, Colaris, Colaris AP, Melaris and theraGuide 5-FU. The separate pharma and research businesses will operate under the name Myriad Pharmaceuticals, and take on the existing ticker symbol MYGN. It will have around 200 employees and focus on forging research partnerships and the development of drugs to treat cancer and infectious diseases. Salt Lake City, Utah-based Myriad first made public its intention to split its pharmaceutical and diagnostic units in September.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel